Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

FDA Approved Drugs: Changes to Approved Drugs01:26

FDA Approved Drugs: Changes to Approved Drugs

85
Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...
85
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

326
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
326
Prescription, Nonprescription and Orphan Drugs01:02

Prescription, Nonprescription and Orphan Drugs

1.0K
Prescription drugs require a prescription from a medical practitioner and can only be obtained from a pharmacy. They have many applications, including treating pain, anxiety, and hypertension.
The misuse and addiction to prescription drugs is a growing problem that can affect people of all age groups, specifically teenagers. This can happen when prescription medications are used in ways not intended by the prescriber, such as taking someone else's prescription or using medication for...
1.0K
Prodrugs01:30

Prodrugs

3.6K
Prodrugs are a class of pharmaceutical compounds that undergo a biotransformation process within the body to be converted into a pharmacologically active drug. Prodrugs are designed to improve the therapeutic properties of the parent drug, such as enhancing bioavailability, increasing stability, or reducing toxicity. The concept of prodrugs revolves around modifying the chemical structure of the original drug to make it more effective or convenient for administration.
Prodrugs help overcome...
3.6K
Drug Administration and Therapy Phases: Overview01:26

Drug Administration and Therapy Phases: Overview

976
Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
976
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents01:20

Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents

818
The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
818

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Needle-Free Dermal Filler Injectors Prompt Safety Warning.

JAMA·2021
Same author

Surgical Staplers to Undergo More Stringent Review for Safety Reasons.

JAMA·2021
Same author

Survey Describes How Patients With Arthritis Get Moving.

JAMA·2021
Same author

UV-C Disinfecting Device Poses Radiation Risk.

JAMA·2021
Same author

Advanced CT Technology Counts Photons to Produce Sharper Images.

JAMA·2021
Same author

COVID-19 Didn't Stop Millions of Youth From Continuing to Vape.

JAMA·2021

Related Experiment Video

Updated: Nov 23, 2025

Mechanical and Controlled PRP Injections in Patients Affected by Androgenetic Alopecia
03:22

Mechanical and Controlled PRP Injections in Patients Affected by Androgenetic Alopecia

Published on: January 27, 2018

15.4K

First Progeria Drug Is Approved

Rebecca Voelker

    JAMA
    |January 5, 2021
    PubMed
    Summary

    No abstract available in PubMed .

    More Related Videos

    Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies
    08:34

    Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

    Published on: February 6, 2019

    20.7K
    Characterizing Exon Skipping Efficiency in DMD Patient Samples in Clinical Trials of Antisense Oligonucleotides
    05:16

    Characterizing Exon Skipping Efficiency in DMD Patient Samples in Clinical Trials of Antisense Oligonucleotides

    Published on: May 7, 2020

    7.1K

    Related Experiment Videos

    Last Updated: Nov 23, 2025

    Mechanical and Controlled PRP Injections in Patients Affected by Androgenetic Alopecia
    03:22

    Mechanical and Controlled PRP Injections in Patients Affected by Androgenetic Alopecia

    Published on: January 27, 2018

    15.4K
    Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies
    08:34

    Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

    Published on: February 6, 2019

    20.7K
    Characterizing Exon Skipping Efficiency in DMD Patient Samples in Clinical Trials of Antisense Oligonucleotides
    05:16

    Characterizing Exon Skipping Efficiency in DMD Patient Samples in Clinical Trials of Antisense Oligonucleotides

    Published on: May 7, 2020

    7.1K